NuCana Plc (NASDAQ:NCNA) shares are trading higher Wednesday after the company was granted a U.S. Patent for phosphoramidate derivatives for use in the treatment of cancer.

The Details:

U.S. Patent #11925658 was granted on Tuesday for "phosphoramidate derivatives for use in the treatment of cancer; especially in the treatment where the patient shows resistance."

NuCana shares are climbing on heavy trading volume Wednesday. According to data from Benzinga Pro, more than 49 million shares have already been traded in the session, compared to the stock's 100-day average of only 438,327 shares.

Related News: What's Going On With 'Bitcoin Developer' MicroStrategy Stock?

Is NCNA A Good Stock To Buy?

An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages – like NuCana's page for example – there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.

These are known as capital allocation programs. NuCana does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's dividend calendar for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.

Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on NuCana will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.

NCNA Price Action: According to Benzinga Pro, NuCana shares are up 52.3% at 58 cents at the time of publication.

Image from Shutterstock